The budget impact of cervical cancer screening using HPV primary screening
In 2014, a human papillomavirus (HPV) test that detects high-risk types and individual genotypes HPV 16 and 18 utilizing amplification of target DNA (the cobas HPV Test) was approved by the FDA for primary screening in cervical cancer. HPV types 16 and 18 have been found to cause more than 70 percent of cervical cancers1; women who are positive for HPV 16 and/or 18 are at an increased risk of high-grade cervical intraepithelial neoplasia (CIN), even if they have normal cytology.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063